Friday, December 17, 2021

As the omicron variant threatens to wipe out monoclonal antibodies, the U.S. is saving up one that will still work/WaPo

Sotrovimab, a treatment from Vir Biotechnology and GlaxoSmithKline, is expected to remain effective against omicron.

With the omicron variant of the coronavirus poised to thwart most covid-19 treatments, U.S. public health officials are stockpiling the one monoclonal antibody that remains effective so that it can be deployed when the variant becomes more prevalent.

The decision to pause every-other-week shipments to states of the treatment, sotrovimab, shortly after Thanksgiving is part of a broader strategy to marshal the most effective tools to combat omicron, according to David Kessler, chief scientific officer of the White House covid-19 response team...

This tells you the feds knew that omicron would only respond to this monoclonal.  But are they testing people for their specific variant before pushing the other monoclonals into their veins?  No. 


Anonymous said...

‘Striking’ vaccine resistance in Omicron variant: Columbia University!

Robert Auld said...

Dr. Shankara Chetty has speculated that omicron is a lab-created variant. As a lay person, I am not competent to judge this. However, the fact that the U.S. Government is already prepared to treat omicron with monoclonal antibodies that work could be consistent with prior knowledge of omicron's characteristics. Given other evidence of planning behind this pandemic, it would make sense to see if there is evidence for this.